Xenotransplantation technology developer eGenesis has raised $125m in a series C round backed by Osage University Partners.
US-based gene-editing technology developer eGenesis closed a $125m series C round yesterday to further advance research conducted at Harvard University.
Spinout-focused investment firm Osage University Partners backed the round, as did Leaps by Bayer and Fresenius Medical Care Ventures, respective vehicles for pharmaceuticals and chemicals producer Bayer and for kidney dialysis centres operator Fresenius Medical Care.
Farallon Capital Management, Polaris Partners, HBM Healthcare Investments, Invus and Samsara BioCapital, LifeSci Venture Partners, Irving Investors, Catalio Capital Management, SymBiosis, Altium Capital, Monashee…
